Merck Sharp & Dohme LLC has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis ...
THE COURT of Tax Appeals (CTA) has ordered the Bureau of Internal Revenue (BIR) to refund P14.59 million to the local branch of United States-based pharmaceutical company Merck Sharp & Dohme (MSD), ...
Merck, Sharp, and Dohme (MSD)’s Keytruda (pembrolizumab) will be available for those with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC), where tumours have ...
Merck Sharp & Dohme LLC has patented new 5,6 saturated bicyclic heterocyles acting as NLRP3 inflammasome inhibitors potentially useful for the treatment of atherosclerosis, metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback